In vitro pore formation and necrosis
Reported within hours of direct cell exposure in cultured cancer cell lines.
Protocol / Research Dosing Guide
PNC-27 Dosage Guide: Preclinical Mechanism, Reconstitution and Safety
An evidence-organized PNC-27 reference that keeps the in vitro membrane-disruption research separate from the community subcutaneous schedules being circulated for a compound with no completed human trial.
Last reviewed September 16, 202617 minute readResearch information only
Level 1 — In vitro and animal mechanism data onlyNo completed human clinical trialNot FDA approved
PNC-27 Quick Start
PNC-27 is a laboratory-derived peptide built from the MDM-2-binding sequence of p53 fused to a membrane-penetrating leader. In vitro work from Hosain, Sarafraz-Yazdi, Bowne, Pincus, Michl and colleagues reports that it binds HDM-2 expressed on the surface of cancer cells and forms membrane pores that cause necrosis, while cells with low membrane HDM-2 are largely spared. This selectivity has been shown in cultured breast, pancreatic, melanoma and leukemia cell lines and in one structural/mechanistic study. No human pharmacokinetic, dosing, or clinical outcome study has been published, and PNC-27 has no FDA-approved use in any condition.
Why researchers care
Selective cancer cell membrane disruption via membrane-bound HDM-2 targeting
Class
26–32 residue chimeric peptide combining a p53 HDM-2-binding domain (residues 12–26) with a penetratin cell-penetrating leader sequence
Route reported
Laboratory work uses direct cell exposure; community sources describe subcutaneous injection
Cycle length
12 weeks on, 8 weeks off reported by a vendor-style source; not validated
Regulatory status
Not FDA approved; experimental with no completed human clinical trial
Loading supplier information
PNC-27 Dosing Protocol and Schedule
The supplied source describes a 10 mg vial reconstituted with 5 mL bacteriostatic water for a 2 mg/mL concentration, with a vendor-style dosing table starting at 2.5 mg once daily for weeks 1–4 and increasing to 5 mg once daily for weeks 5–12, framed as an experimental protocol requiring physician supervision and explicitly stating no completed human trials exist.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Weeks 1–4 | 2.5 mg once daily, morning | Vendor-style source; not a tested human dose |
| Weeks 5–12 | 5 mg once daily, morning | Vendor-style source; not a tested human dose |
| Cycle length | 12 weeks on | Vendor-style source |
| Off period | 8 weeks off before any resumption | Vendor-style source |
| In vitro exposure | Direct cell culture exposure at laboratory-determined concentrations | Laboratory research only |
No human trial has tested any PNC-27 dose, schedule, or cycle length. The milligram figures above are a vendor-authored injectable structure built around a 10 mg vial, not a result derived from human pharmacokinetic or dose-finding data.
PNC-27 Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Bacteriostatic water at a measured volume
Research planning item
U-100 insulin syringes
Research planning item
Alcohol prep swabs
Research planning item
Sharps container
Research planning item
Refrigeration for the prepared vial
Research planning item
Written concentration label with the preparation date
PNC-27 Reconstitution Calculator
Vial-format concentration math
Concentration
2 mg/mL
Draw volume
1.25 mL
U-100 units
125
Mathematical draws
2
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take PNC-27: Morning or Night?
Morning or evening?
Morning is the pattern described in vendor-style material; no study compared times of day.
Daily or spaced?
Once daily is the vendor-described pattern; no dose-finding study exists.
With food?
Not applicable to an injected product.
Missed amount?
No validated replacement procedure exists.
PNC-27 Route Comparison
| Format | What is reported | Evidence limit |
|---|---|---|
| Direct cell exposure (in vitro) | Laboratory concentrations applied to cultured cancer and normal cell lines | The only setting with controlled selectivity data |
| Subcutaneous injection | 2.5–5 mg once daily in vendor-style sources | No published human pharmacokinetic or safety study |
| Route conversion | Not established | In vitro membrane-binding concentrations cannot be converted into a systemic injected dose |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
PNC-27 Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Human plasma half-life | Not established | No human PK study exists |
| Animal half-life | Not established in the sources reviewed | No published animal PK study was identified |
| Systemic distribution to membrane-HDM-2 sites | Not established | Mechanism was demonstrated in direct cell exposure, not through circulation in a living organism |
| Frequency logic | Once daily is a vendor convention | Not derived from pharmacokinetics |
PNC-27 Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| Subcutaneous | 2.5 mg | Once daily | Vendor-style source | No |
| Subcutaneous | 5 mg | Once daily | Vendor-style source | No |
| In vitro | Laboratory-determined concentrations | Direct exposure | Cell-culture research | Not applicable to human dosing |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
PNC-27 Reconstitution Guide
Concentration: 2 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 2.5 mg | 1.25 mL | 125 units |
| 5 mg | 2.5 mL | 250 units |
- 1.Confirm the exact quantity printed on the vial.
- 2.Draw the bacteriostatic water in measured increments; 10 mg into 5 mL gives 2 mg/mL.
- 3.Clean the stopper with an alcohol swab.
- 4.Add the liquid slowly down the vial wall.
- 5.Swirl gently until clear; never shake.
- 6.Inspect for cloudiness, color or particles and discard anything that is not clear.
- 7.Label the vial with the concentration and the preparation date.
- 8.Refrigerate at 2–8 °C and use the prepared vial within the window stated on the product label.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How PNC-27 Works
Structure
PNC-27 fuses residues 12–26 of p53, the MDM-2/HDM-2-binding segment, to a penetratin-derived membrane-penetrating leader sequence.
PNC-27 Human Trials and FDA Status
Current status · verified September 16, 2026
Not FDA approved; experimental with no completed human clinical trial
- Hosain and colleagues, and later Sarafraz-Yazdi, Bowne, Pincus and Michl, reported in vitro selectivity of PNC-27 for HDM-2-overexpressing cancer cells over normal cells across multiple cell-line studies.
- A 2010 PNAS study demonstrated that transfecting membrane-localized HDM-2 into resistant normal cells rendered them susceptible to PNC-27, supporting a membrane-HDM-2-dependent mechanism.
- A 2020 in vitro study extended this selectivity to acute leukemia cell lines (U937, OCI-AML3, HL-60).
- A 2024 study reported that PNC-27 also disrupts mitochondrial membranes in treated cancer cells, in addition to plasma-membrane pore formation.
- No completed human clinical trial of PNC-27 has been published as of the review date, and no in vivo animal efficacy or toxicology study was identified in the sources reviewed.
Who Should Avoid PNC-27?
This is an evidence-gap and precaution list, not an approved prescribing label.
Anyone without direct oncology physician supervision
The compound is experimental with no established human safety profile
Pregnancy or breastfeeding
No safety data
Children or adolescents
No safety data
Concurrent chemotherapy without specialist oversight
No human combination-safety data exists despite a theoretical non-overlapping mechanism
Anyone expecting a proven cancer treatment
No human efficacy has been demonstrated; only in vitro selectivity has been shown
Long-term or repeated use outside monitored research
No long-term human safety data
PNC-27 Side Effects, Risks and Safety
Injection-site redness or indurationReported as a theoretical concern in vendor-style material
Important limitation: Consistent with the peptide's membrane-active mechanism; not measured in humans.
Hepatocyte stress at high exposureTheoretical
Important limitation: Raised in vendor-style tracking guidance; no human liver-safety data exists.
Systemic toxicityUnknown
Important limitation: No human toxicology study was identified.
Immune response to necrotic cell death (DAMP release)Theoretical, proposed as a potential benefit
Important limitation: Not measured as a safety or efficacy outcome in humans.
Drug interactionsUnknown
Important limitation: No interaction studies.
Long-term effectsUnknown
Important limitation: No human follow-up data exists.
PNC-27 Timeline and Monitoring
Human onset or effect timeline
Not established; no human trial has measured this.
Vendor-style 12-week cycle
A vendor construction, not a measured clinical timeline.
Monitoring
No validated PNC-27 human monitoring schedule or stopping rule exists.
PNC-27 Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Selective cancer cell membrane disruption | In vitro | Multiple cell-line studies from the same research group | Not demonstrated in living humans |
| Sparing of normal cells with low membrane HDM-2 | In vitro | Comparative cell-line exposure studies | Selectivity margin in vivo is unknown |
| Activity against leukemia cell lines | In vitro | 2020 leukemia cell-line study | No animal or human leukemia outcome data |
| Adjunct use with chemotherapy | Not established | Theoretical, based on mechanism difference | No human combination data |
PNC-27 Storage and Handling
Lyophilized powder
Store at -20 °C for maximum stability, per vendor-style labeling.
Reconstituted vial
Refrigerate at 2–8 °C; vendor-style sources describe use within about 14 days, though no independent third-party stability study was identified.
Light
Protect the vial from light.
Appearance
A clear, colorless solution is expected; cloudiness or particles mean discard.
PNC-27 Troubleshooting
Solution appears cloudy
Discard and do not inject; appearance cannot confirm sterility.
Calculated units look wrong
Recheck vial quantity, diluent volume, target amount and U-100 conversion.
Considering use without oncology supervision
This is an experimental compound with no completed human trial; physician oversight is described as mandatory in the source material.
Unexpected symptoms occur
No PNC-27 human safety protocol exists; seek licensed clinical review immediately.
A scheduled dose is missed
No validated missed-dose procedure exists.
PNC-27 Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| PNC-27 | p53/HDM-2-targeting membrane-active peptide | In vitro and cell-line mechanism data only | No completed human trial |
| PNC-28 | Related p53-derived penetratin peptide | In vitro pancreatic cancer necrosis studies | No completed human trial |
| LL-37 | Human host-defense peptide with membrane activity | Published topical human trials for wound healing | Different target and different evidence level |
| KPV | Anti-inflammatory tripeptide fragment | Primarily laboratory and preclinical | Different mechanism and target |
PNC-27 Frequently Asked Questions
What is PNC-27?
A 26-residue chimeric peptide combining the MDM-2-binding segment of p53 with a penetratin cell-penetrating leader sequence.
Is PNC-27 FDA approved?
No. It is experimental with no completed human clinical trial.
What has actually been shown?
In vitro studies report that it selectively disrupts the membranes of cancer cells that overexpress HDM-2 on their surface, sparing normal cells with low membrane HDM-2.
Is there a validated human dose?
No. The milligram schedules circulated online are vendor constructions, not results of a human dose-finding trial.
Does it cause apoptosis?
No. Published mechanism work describes necrotic cell death from membrane pore formation, not caspase-driven apoptosis.
What cancers show HDM-2 overexpression?
In vitro literature associates membrane HDM-2 overexpression with a subset of sarcomas, glioblastoma, breast carcinoma, melanoma and certain leukemias, but this describes laboratory cell-line findings, not a validated human treatment indication.
Is it safe to combine with chemotherapy?
Unknown. No human combination-safety data exists; any theoretical non-overlapping toxicity profile is unproven in humans.
What is its half-life?
Not established. No published human or animal pharmacokinetic study was identified.
Can a physician legally supervise its use?
Vendor-style sources describe physician supervision as required for any experimental use, but this does not constitute FDA approval or an established treatment pathway.
What does the calculator do?
It converts entered vial and liquid values into concentration and U-100 volume math only; it does not establish a dose.
Is long-term safety known?
No. No human safety database exists for PNC-27.
Sources and Research
Coverage source
1. PNC-27 protocol coverage source
Vendor-style dosing table, reconstitution math and tracking guidance; not primary evidence.
Open direct sourceLaboratory research
2. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
In vitro study showing membrane-HDM-2-dependent selective cytotoxicity, including transfection experiments in resistant normal cells.
Open direct sourceLaboratory research
3. Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
In vitro study extending PNC-27 selectivity findings to acute leukemia cell lines.
Open direct sourceLaboratory research
4. Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
2024 in vitro study reporting additional mitochondrial membrane disruption alongside plasma-membrane pore formation.
Open direct sourceMissing information flagged for review
- Completed human clinical trial: Not established
- Human pharmacokinetics and half-life: Not established
- In vivo animal efficacy and toxicology data: Not established
- Validated human dose, schedule, and cycle length: Not established
- Long-term human safety data: Not established
- Chemotherapy combination safety data: Not established
- Compound-specific prepared-vial stability duration: Not established